Sign In
Buy STRO
$23.57
-0.160 (-0.674%)
At Close: Jul 17, 2026
Sutro Biopharma to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 06'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
04:05pm, Thursday, 04'th Jan 2024
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer
Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement
04:11pm, Friday, 29'th Dec 2023
Positive results achieved from phase 1 dose expansion study using luveltamab tazevibulin for the treatment of patients with FRa-positive endometrial cancer. Phase 1 dose expansion study, using luvelta
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
04:05pm, Monday, 04'th Dec 2023
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
04:05pm, Tuesday, 21'st Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
04:30pm, Monday, 13'th Nov 2023
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 -
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
09:47am, Monday, 13'th Nov 2023
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Luvelta demonstrate d encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα
Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
09:48am, Monday, 09'th Oct 2023
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancers. The company will present results from a phase 1
Sutro Biopharma to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 30'th Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
07:46pm, Thursday, 10'th Aug 2023
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.55 per share a year ago.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Monday, 15'th May 2023
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
08:00am, Monday, 08'th May 2023
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format a
